82 FR 40008 - Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 162 (August 23, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 162 (August 23, 2017)
| Page Range | 40008-40008 | |
| FR Document | 2017-17961 |
[Federal Register Volume 82, Number 162 (Wednesday, August 23, 2017)] [Notices] [Page 40008] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-17961] [[Page 40008]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket Nos. FDA-2013-E-0264; FDA-2013-E-0263; and FDA-2013-E-0218] Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation AGENCY: Food and Drug Administration, HHS. ACTION: Notification of affirmation. ----------------------------------------------------------------------- DATES: August 23, 2017 FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, 10903 New Hampshire Ave., Bldg. 51, Silver Spring, MD 20993, 301-796-9148. SUPPLEMENTARY INFORMATION: The Food and Drug Administration (FDA) is affirming the signature date for a notice that appeared in the Federal Register on August 21, 2017 (82 FR 39587). The document announced FDA's determination for the regulatory review period for RECUVYRA. The document published with an incorrect date for the signature. We affirm that the document was signed on August 15, 2017. Dated: August 21, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017-17961 Filed 8-21-17; 4:15 pm] BILLING CODE 4164-01-P
![40008 Federal Register / Vol. 82, No. 162 / Wednesday, August 23, 2017 / Notices
DEPARTMENT OF HEALTH AND ADDRESSES: You may submit either copies total. One copy will include the
HUMAN SERVICES electronic or written comments on information you claim to be confidential
Agency guidances at any time as with a heading or cover note that states
Food and Drug Administration follows: ‘‘THIS DOCUMENT CONTAINS
[Docket Nos. FDA–2013–E–0264; FDA– CONFIDENTIAL INFORMATION.’’ The
Electronic Submissions
2013–E–0263; and FDA–2013–E–0218] Agency will review this copy, including
Submit electronic comments in the the claimed confidential information, in
Determination of Regulatory Review following way: its consideration of comments. The
Period for Purposes of Patent • Federal eRulemaking Portal: second copy, which will have the
Extension; RECUVYRA; Affirmation https://www.regulations.gov. Follow the claimed confidential information
instructions for submitting comments. redacted/blacked out, will be available
AGENCY: Food and Drug Administration, Comments submitted electronically, for public viewing and posted on
HHS. including attachments, to https:// https://www.regulations.gov. Submit
ACTION: Notification of affirmation. www.regulations.gov will be posted to both copies to the Dockets Management
the docket unchanged. Because your Staff. If you do not wish your name and
DATES: August 23, 2017 comment will be made public, you are contact information to be made publicly
FOR FURTHER INFORMATION CONTACT: solely responsible for ensuring that your available, you can provide this
Joyce Strong, Office of Policy, 10903 comment does not include any information on the cover sheet and not
New Hampshire Ave., Bldg. 51, Silver confidential information that you or a in the body of your comments and you
Spring, MD 20993, 301–796–9148. third party may not wish to be posted, must identify this information as
SUPPLEMENTARY INFORMATION: The Food such as medical information, your or ‘‘confidential.’’ Any information marked
and Drug Administration (FDA) is anyone else’s Social Security number, or as ‘‘confidential’’ will not be disclosed
affirming the signature date for a notice confidential business information, such except in accordance with 21 CFR 10.20
that appeared in the Federal Register on as a manufacturing process. Please note and other applicable disclosure law. For
August 21, 2017 (82 FR 39587). The that if you include your name, contact more information about FDA’s posting
document announced FDA’s information, or other information that of comments to public dockets, see 80
determination for the regulatory review identifies you in the body of your FR 56469, September 18, 2015, or access
period for RECUVYRA. The document comments, that information will be the information at: https://www.gpo.gov/
published with an incorrect date for the posted on https://www.regulations.gov. fdsys/pkg/FR-2015-09-18/pdf/2015-
signature. We affirm that the document • If you want to submit a comment 23389.pdf.
was signed on August 15, 2017. with confidential information that you Docket: For access to the docket to
Dated: August 21, 2017. do not wish to be made available to the read background documents or the
Leslie Kux, public, submit the comment as a electronic and written/paper comments
Associate Commissioner for Policy. written/paper submission and in the received, go to https://
[FR Doc. 2017–17961 Filed 8–21–17; 4:15 pm]
manner detailed (see ‘‘Written/Paper www.regulations.gov and insert the
Submissions’’ and ‘‘Instructions’’). docket number, found in brackets in the
BILLING CODE 4164–01–P
Written/Paper Submissions heading of this document, into the
‘‘Search’’ box and follow the prompts
Submit written/paper submissions as
DEPARTMENT OF HEALTH AND and/or go to the Dockets Management
follows:
HUMAN SERVICES Staff, 5630 Fishers Lane, Rm. 1061,
• Mail/Hand delivery/Courier (for
Rockville, MD 20852.
Food and Drug Administration written/paper submissions): Dockets
Submit written requests for single
Management Staff (HFA–305), Food and
[Docket No. FDA–2016–D–1248] copies of the guidance to the Policy and
Drug Administration, 5630 Fishers
Regulations Staff (HFV–6), Center for
Lane, Rm. 1061, Rockville, MD 20852.
Oncology Drugs for Companion Veterinary Medicine, Food and Drug
• For written/paper comments
Animals; Guidance for Industry; Administration, 7519 Standish Pl.,
submitted to the Dockets Management
Availability Rockville, MD 20855. Send one self-
Staff, FDA will post your comment, as
addressed adhesive label to assist that
AGENCY: Food and Drug Administration, well as any attachments, except for
office in processing your requests. See
HHS. information submitted, marked and
the SUPPLEMENTARY INFORMATION section
ACTION: Notice of availability. identified, as confidential, if submitted
for electronic access to the guidance
as detailed in ‘‘Instructions.’’
SUMMARY: The Food and Drug Instructions: All submissions received document.
Administration (FDA or Agency) is must include the Docket No. FDA– FOR FURTHER INFORMATION CONTACT:
announcing the availability of a 2016–D–1248 for ‘‘Oncology Drugs for Christopher Loss, Center for Veterinary
guidance for industry #237 entitled Companion Animals.’’ Received Medicine (HFV–116), Food and Drug
‘‘Oncology Drugs for Companion comments will be placed in the docket Administration, 7500 Standish Pl., Rm.
Animals.’’ The guidance provides and, except for those submitted as N310, Rockville, MD 20855, 240–402–
recommendations for sponsors of ‘‘Confidential Submissions,’’ publicly 0619, christopher.loss@fda.hhs.gov.
investigational oncology drugs for use in viewable at https://www.regulations.gov SUPPLEMENTARY INFORMATION:
companion animals (e.g., dogs, cats, and
asabaliauskas on DSKBBXCHB2PROD with NOTICES
or at the Dockets Management Staff
horses), discusses the contents of a new office between 9 a.m. and 4 p.m., I. Background
animal drug application for certain Monday through Friday. In the Federal Register of June 10,
oncology drugs, and provides • Confidential Submissions—To 2016 (81 FR 37605), FDA published the
recommendations on how to address submit a comment with confidential notice of availability for a draft guidance
human user safety concerns. information that you do not wish to be entitled ‘‘Oncology Drugs for
DATES: The announcement of the made publicly available, submit your Companion Animals’’ giving interested
guidance is published in the Federal comments only as a written/paper persons until August 9, 2016, to
Register on August 23, 2017. submission. You should submit two comment on the draft guidance. FDA
VerDate Sep<11>2014 16:47 Aug 22, 2017 Jkt 241001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\23AUN1.SGM 23AUN1](https://thefederalregister.org/doc/82_FR_40170/page/1.svg)
Document Created: 2017-08-22 23:52:15
Document Modified: 2017-08-22 23:52:15
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notification of affirmation. | |
| Dates | August 23, 2017 | |
| Contact | Joyce Strong, Office of Policy, 10903 New Hampshire Ave., Bldg. 51, Silver Spring, MD 20993, 301-796-9148. | |
| FR Citation | 82 FR 40008 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR